Marshall Wace
IMRX icon

Marshall Wace’s Immuneering IMRX Stock Holding History

Marshall Wace’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.65M Sell
731,897
-1,264,688
-63% -$6.4M ﹤0.01% 1532
2026
Q1 		$10.5M Buy
1,996,585
+1,284,710
+180% +$6.59M 0.01% 957
2025
Q4 		$4.68M Buy
711,875
+440,571
+162% +$2.83M ﹤0.01% 1186
2025
Q3 		$1.9M Sell
271,304
-302,560
-53% -$1.57M ﹤0.01% 1650
2025
Q2 		$1.93M Sell
573,864
-234,105
-29% -$401K ﹤0.01% 1578
2025
Q1 		$1.23M Buy
807,969
+786,537
+3,670% +$1.43M ﹤0.01% 1692
2024
Q4 		$47.1K Buy
+21,432
New +$44.4K ﹤0.01% 2488
2024
Q3 		– Sell
-384,075
Closed -$492K – 2717
2024
Q2 		$492K Buy
+384,075
New +$631K ﹤0.01% 1963
2022
Q4 		– Sell
-67,160
Closed -$962K – 3159
2022
Q3 		$962K Buy
+67,160
New +$533K ﹤0.01% 2429
2021
Q4 		– Sell
-13,149
Closed -$349K – 4058
2021
Q3 		$349K Buy
+13,149
New +$353K ﹤0.01% 2580

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Marshall Wace's IMRX Position: Q2 2026 in Review

Marshall Wace reduced its Immuneering (IMRX) stake by 63% in Q2 2026, selling an estimated $6.4M and leaving 731,897 shares worth $3.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1532.

Marshall Wace first reported a position in IMRX in Q3 2021 and has held it in 10 quarters since. The position peaked at $10.5M in Q1 2026. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Marshall Wace held 731,897 shares of Immuneering worth $3.65M as of Q2 2026.
  • Marshall Wace sold 1,264,688 Immuneering shares in Q2 2026, an estimated $6.4M.
  • Immuneering made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1532 holding.
  • Marshall Wace first reported a position in Immuneering in Q3 2021 and has held it in 10 quarters since.
  • Marshall Wace's Immuneering position peaked at $10.5M in Q1 2026.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.